Table. 5—

5 Adverse events noted by>10% of patients

Body system/adverse events	n	%
Aggravated pulmonary hypertension	56	33.1
Headache	53	31.4
Upper respiratory tract infection	36	21.3
Chest pain	32	18.9
Dizziness (except vertigo)	29	17.2
Dyspnoea	27	16.0
Flushing	24	14.2
Nasopharyngitis	24	14.2
Diarrhoea	23	13.6
Syncope	23	13.6
Abnormal hepatic function	22	13.0
Bronchitis	20	11.8
Nausea	20	11.8
Cardiac failure	19	11.2
Leg oedema	19	11.2
Cough	18	10.7
Pain in limb	18	10.7
Arthralgia	17	10.1
Palpitations	17	10.1

Adverse events were collected from the 169 patients during adverse event reporting periods only. The mean duration of observation for adverse events was 78±28 weeks (±sd, median 77 weeks).